Cerebrovascular disorder

Summary

Cerebrovascular disorder (MONDO:0011057) is a disease (an umbrella term covering 24 Mondo subtypes) caused by NIT1 (GenCC Strong), with 1 cohort gene (57 GWAS associations across 55 studies) and 6,214 clinical trials. Top therapeutic interventions include aspirin, alteplase, and clopidogrel.

At a glance

• Causal gene: NIT1 (GenCC Strong)
• Umbrella term: 24 Mondo subtypes
• Cohort genes: 1
• GWAS associations: 57
• Clinical trials: 6,214

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cerebrovascular disorder
Mondo ID	MONDO:0011057
EFO	EFO:0003763
MeSH	D002561
DOID	DOID:6713
ICD-10-CM	I60-I69
ICD-11	843843448
NCIT	C2938
SNOMED CT	62914000
UMLS	C0007820
MedGen	858
Anatomy (UBERON)	UBERON:0008998
Is cancer (heuristic)	no

Also known as: cerebral infarction · cerebrovascular accident · cerebrovascular disease · cerebrovascular disorder · CVA · CVA (cerebral vascular accident) · stroke

Data availability: 57 GWAS associations (55 studies) · 1 GenCC gene-disease record · 3 cell lines.

Disease family

An umbrella term covering 24 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › cerebrovascular disorder

Related subtypes (70): leukoencephalopathy, megalencephalic, encephalopathy, acute, infection-induced, diabetic encephalopathy, complex cortical dysplasia with other brain malformations, hydrocephalus, brain compression, cerebral sarcoidosis, hepatic encephalopathy, visual pathway disorder, central nervous system origin vertigo, cerebellar disorder, cerebritis, olfactory nerve disorder, thalamic disorder, pituitary gland disorder, disorder of optic chiasm, basal ganglia disorder, epilepsy, mental disorder, central nervous system cyst, migraine disorder, multiple sclerosis, prion disease, carbon monoxide-induced delayed encephalopathy, cerebral malaria, akinetic mutism, bulbar polio, Reye syndrome, brain edema, encephalomalacia, intracranial hypertension, intracranial hypotension, Wernicke encephalopathy, encephalopathy, recurrent, of childhood, XK aprosencephaly, progressive bulbar palsy, glycine encephalopathy, autosomal recessive frontotemporal pachygyria, occipital pachygyria and polymicrogyria, insomnia, narcolepsy-cataplexy syndrome, megalencephaly, meningoencephalocele, cerebral cortical dysplasia, encephaloclastic disorder, bilirubin encephalopathy, autoimmune encephalopathy with parasomnia and obstructive sleep apnea, narcolepsy without cataplexy, hypothalamic hamartomas with gelastic seizures, encephalitis, cerebral lipidosis with dementia, brain neoplasm, colpocephaly, corpus callosum agenesis of blepharophimosis robin type, corpus callosum dysgenesis X-linked recessive, corpus callosum dysgenesis cleft spasm, corpus callosum dysgenesis hypopituitarism, cerebral degeneration, acute bilirubin encephalopathy, chronic bilirubin encephalopathy, atelencephaly, aprosencephaly, brain injury, traumatic encephalopathy, cluster headache syndrome, cerebral cortex disorder, midbrain disorder, encephalopathy due to mitochondrial and peroxisomal fission defect, brain malformations with or without urinary tract defects, encephalopathy, acute transient

Subtypes (24): cerebral arteritis, intracranial thrombosis, occlusion precerebral artery, vascular dementia, stroke disorder, internal carotid artery stenosis, carotid artery disorder, brain ischemia, brain infarction, cerebral amyloid angiopathy, vascular brain injury, basal ganglia cerebrovascular disorder, intracranial arterial disease, intracranial vasospasm, subclavian steal syndrome, pseudotumor cerebri, cerebral sinovenous thrombosis, HTRA1-related autosomal dominant cerebral small vessel disease, familial porencephaly, microangiopathy and leukoencephalopathy, pontine, autosomal dominant, cathepsin a-related arteriopathy-strokes-leukoencephalopathy, precerebral artery stenosis, cerebral artery stenosis, APP-related brain and vascular amyloidosis

Genetics & variants

GWAS landscape

57 GWAS associations across 55 studies. Top hits map to 11 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs1537373	3e-34	CDKN2B-AS1	T	0.07
chr7:19052733	1e-31		G	0.1
rs1333047	1e-26	CDKN2B-AS1	A	0.07
rs10455872	8e-26	LPA	A	0.12
rs2107595	2e-23	HDAC9 - TWIST1	G	0.08
chr19:44908684	7e-22		C	0.12
chr11:102718695	2e-19		T	0.07
rs13225723	8e-18	LINC02577	G	0.06
chr7:92237533	5e-16		A	0.06
rs4272	2e-14	CDK6	A	0.05
rs1892971	4e-14	RNU7-159P - MMP13	G	0.06
rs429358	5e-14	APOE	T	0.06
chr19:11191677	9e-13		T	0.06
rs646776	3e-12	CELSR2 - PSRC1	C	0.05
chr16:75462055	3e-12		A	0.04
chr4:148378442	5e-12		T	0.06
chr3:11358566	6e-12		G	0.04
chr9:22103184	7e-12		T	0.07
chr2:26914364	1e-11		C	0.04
rs3184504	2e-11	ATXN2, SH2B3	T	0.04
rs12151108	2e-11	SMARCA4 - LDLR	G	0.06
rs1275982	4e-11	KCNK3	C	0.04
rs185438795	1e-10	CYP4F8 - CYP4F3	?
chr10:103854694	1e-10		T	0.06
chr1:3195426	7e-10		T	1.4
chr9:22085599	1e-09		C	0.08
chr8:104510437	1e-09		G	2.01
chr9:98182841	1e-09		T	1.74
chr2:202943809	2e-09		A	0.11
rs61411276	3e-09	PITX2 - LINC01438	?	1.11

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90475985	Verma A	2024	69,894	349,486	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90473581	UK Biobank Whole-Genome Sequencing Consortium	2025	24,515	433,925	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90103647	Rannikmae K	2022	19,449	388,761	Physician-Confirmed and Administrative Definitions of Stroke in UK Biobank Reflect the Same Underlying Genetic Trait.
GCST90477982	Verma A	2024	16,858	97,523	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480195	Verma A	2024	16,858	97,523	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90103644	Rannikmae K	2022	16,750	391,460	Physician-Confirmed and Administrative Definitions of Stroke in UK Biobank Reflect the Same Underlying Genetic Trait.
GCST90651254	Liu TY	2025	14,440	215,981	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90478003	Verma A	2024	14,431	426,248	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90103642	Rannikmae K	2022	12,612	395,598	Physician-Confirmed and Administrative Definitions of Stroke in UK Biobank Reflect the Same Underlying Genetic Trait.
GCST90478000	Verma A	2024	12,412	432,840	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	2
Tier 2: splice/UTR	1
Tier 3: regulatory	3
Tier 4: intronic/intergenic	43

MAF distribution

Bucket	Variants
common (>=0.05)	25
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	24

Functional consequences

Consequence	Count
unknown	29
intron_variant	8
intergenic_variant	6
regulatory_region_variant	3
missense_variant	2
3_prime_UTR_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs1537373	9	22103342	T>A,G	0.498	intron_variant	CDKN2B-AS1	3e-34	Tier 4: intronic/intergenic
chr7:19052733				0.16			1e-31	Tier 4: intronic/intergenic
rs1333047	9	22124505	A>C,G,T	0.422	intergenic_variant	CDKN2B-AS1	1e-26	Tier 4: intronic/intergenic
rs10455872	6	160589086	A>G	0.069	intron_variant	LPA	8e-26	Tier 4: intronic/intergenic
rs2107595	7	19009765	G>A,C,T	0.182	regulatory_region_variant	HDAC9 - TWIST1	2e-23	Tier 3: regulatory
chr19:44908684							7e-22	Tier 4: intronic/intergenic
chr11:102718695				0.184			2e-19	Tier 4: intronic/intergenic
rs13225723	7	106776021	G>A,C	0.204	intron_variant	LINC02577	8e-18	Tier 4: intronic/intergenic
chr7:92237533				0.21			5e-16	Tier 4: intronic/intergenic
rs4272	7	92607515	A>G,T	0.207	3_prime_UTR_variant	CDK6	2e-14	Tier 2: splice/UTR
rs1892971	11	102924877	G>A	0.188	regulatory_region_variant	RNU7-159P - MMP13	4e-14	Tier 3: regulatory
rs429358	19	44908684	T>C	0.14	missense_variant	APOE	5e-14	Tier 1: coding
chr19:11191677				0.121			9e-13	Tier 4: intronic/intergenic
rs646776	1	109275908	C>A,G,T	0.22	regulatory_region_variant	CELSR2 - PSRC1	3e-12	Tier 3: regulatory
chr16:75462055				0.425			3e-12	Tier 4: intronic/intergenic
chr4:148378442				0.14			5e-12	Tier 4: intronic/intergenic
chr3:11358566				0.388			6e-12	Tier 4: intronic/intergenic
chr9:22103184							7e-12	Tier 4: intronic/intergenic
chr2:26914364				0.394			1e-11	Tier 4: intronic/intergenic
rs3184504	12	111446804	T>A,C,G	0.491	missense_variant	ATXN2, SH2B3	2e-11	Tier 1: coding
rs12151108	19	11086585	G>A,T	0.12	intergenic_variant	SMARCA4 - LDLR	2e-11	Tier 4: intronic/intergenic
rs1275982	2	26696221	C>T	0.47	intron_variant	KCNK3	4e-11	Tier 4: intronic/intergenic
rs185438795	19	15637050	A>G		intergenic_variant	CYP4F8 - CYP4F3	1e-10	Tier 4: intronic/intergenic
chr10:103854694							1e-10	Tier 4: intronic/intergenic
chr1:3195426							7e-10	Tier 4: intronic/intergenic
chr9:22085599							1e-09	Tier 4: intronic/intergenic
chr8:104510437							1e-09	Tier 4: intronic/intergenic
chr9:98182841							1e-09	Tier 4: intronic/intergenic
chr2:202943809							2e-09	Tier 4: intronic/intergenic
rs61411276	4	110776660	TG>T,TGG	0.05	intergenic_variant	PITX2 - LINC01438	3e-09	Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 1 · Orphanet: 0 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
NIT1	Strong	Autosomal recessive	cerebrovascular disorder

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
NIT1	HGNC:7828	ENSG00000158793	Q86X76	Deaminated glutathione amidase	gencc

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
NIT1	Deaminated glutathione amidase	Catalyzes the hydrolysis of the amide bond in N-(4-oxoglutarate)-L-cysteinylglycine (deaminated glutathione), a metabolite repair reaction to dispose of the harmful deaminated glutathione.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Other/Unknown	1	1.8×	0.558

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
NIT1	Other/Unknown	no		UPF0012_CS, C-N_Hydrolase, C-N_Hydrolase_sf

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
left adrenal gland	1
right adrenal gland	1
right adrenal gland cortex	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
NIT1	287	ubiquitous	marker	right adrenal gland cortex, right adrenal gland, left adrenal gland

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
NIT1	1,658

Structural data

PDB: 0 · AlphaFold-only: 1 · No structure: 0

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
NIT1	Q86X76	88.57

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 0. Enrichment computed across 1 evidence-associated genes (0 with Reactome annotation).

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
obsolete amide catabolic process	1	2106.5×	5e-04	NIT1

Therapeutics

Drugs indicated for this disease

0 approved, 8 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Aspirin	Phase 3 (in late-stage trials)
Atenolol	Phase 3 (in late-stage trials)
Chlorthalidone	Phase 3 (in late-stage trials)
Cilostazol	Phase 3 (in late-stage trials)
Gefarnate	Phase 3 (in late-stage trials)
Reserpine	Phase 3 (in late-stage trials)
Urapidil	Phase 3 (in late-stage trials)
Vitamin E	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Lovastatin.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
NIT1	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
NIT1	2	Binding:2

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	NIT1

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
NIT1	2	—

Clinical trials & evidence

Clinical trials

Clinical trials: 6,214.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	265
PHASE3	215
PHASE4	183
PHASE1	136
Not specified	112
PHASE1/PHASE2	87
PHASE2/PHASE3	51
EARLY_PHASE1	51

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02472028	PHASE4	RECRUITING	Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals
NCT02670161	PHASE4	ENROLLING_BY_INVITATION	Quality Improvement and Practice Based Research in Neurology Using the EMR
NCT03568890	PHASE4	ACTIVE_NOT_RECRUITING	Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure
NCT03862859	PHASE4	RECRUITING	The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis
NCT03968393	PHASE4	RECRUITING	Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
NCT04436978	PHASE4	RECRUITING	What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?
NCT04908423	PHASE4	RECRUITING	Xeomin® and Gait Related Mobility After Stroke
NCT05169021	PHASE4	NOT_YET_RECRUITING	Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD
NCT05260125	PHASE4	RECRUITING	Comparison of the Efficacy of Ultrasound Guided vs Non-guided Suprascapular Nerve Block Treatment in Stroke Patients
NCT05284747	PHASE4	ACTIVE_NOT_RECRUITING	EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
NCT05995600	PHASE4	RECRUITING	Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE
NCT06108414	PHASE4	RECRUITING	Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation
NCT06429332	PHASE4	RECRUITING	International Care Bundle Evaluation in Cerebral Hemorrhage Research
NCT06486792	PHASE4	NOT_YET_RECRUITING	Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation
NCT06526117	PHASE4	RECRUITING	Stroke Prevention in Nigeria 2 Trial
NCT06543758	PHASE4	RECRUITING	Effectiveness and Safety of At-home Gait Rehabilitation Using Wearable Exoskeletal Robot
NCT06757764	PHASE4	RECRUITING	The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis
NCT06823999	PHASE4	NOT_YET_RECRUITING	Prevention and Treatment for Bruises in Patients With Ischemic Stroke
NCT06897176	PHASE4	RECRUITING	Effects of Cerebrolysin on Language Ability in Non-fluent Aphasia Patients After Stroke: A Randomized, Placebo-controlled, Double-blinded, Single Center Study
NCT06899464	PHASE4	NOT_YET_RECRUITING	Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial
NCT06921616	PHASE4	NOT_YET_RECRUITING	Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Lobar Intracerebral Hemorrhage at the Early Stage.
NCT06924983	PHASE4	NOT_YET_RECRUITING	Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Basal Ganglia Intracerebral Hemorrhage at the Early Stage
NCT06959784	PHASE4	ENROLLING_BY_INVITATION	Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)
NCT07049094	PHASE4	RECRUITING	The Analgesic Effect of Scalp Nerve Block Using Bupivacaine Liposomes for Postoperative Pain Relief After Craniotomy
NCT07095790	PHASE4	RECRUITING	Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke
NCT07111559	PHASE4	RECRUITING	Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trial
NCT07237308	PHASE4	NOT_YET_RECRUITING	BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis
NCT07519044	PHASE4	RECRUITING	Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion
NCT07563673	PHASE4	NOT_YET_RECRUITING	Early Low-dose ASpirin Use After Intravenous Thrombolysis for Acute Ischemic Cerebral Infarction（ELASTIC）
NCT00004727	PHASE4	COMPLETED	Antiplatelet Therapy to Prevent Stroke in African Americans
NCT00029172	PHASE4	COMPLETED	Treatment for Post-Stroke Depression
NCT00079638	PHASE4	COMPLETED	Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL
NCT00101543	PHASE4	COMPLETED	Gait Training For Acute Stroke: Functional Neuromuscular Stimulation (FNS) and Weight Supported Treadmill Training
NCT00102869	PHASE4	COMPLETED	Dopaminergic Enhancement of Learning and Memory in Aphasia
NCT00106886	PHASE4	UNKNOWN	HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study)
NCT00108706	PHASE4	UNKNOWN	Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)
NCT00126087	PHASE4	TERMINATED	Potentiation of Procedural Motor Learning in Health and Disease
NCT00130039	PHASE4	COMPLETED	Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II
NCT00149227	PHASE4	COMPLETED	Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)
NCT00153062	PHASE4	COMPLETED	PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ASPIRIN	4	55
ALTEPLASE	4	19
CLOPIDOGREL	4	18
CILOSTAZOL	4	15
TENECTEPLASE	4	12
WARFARIN	4	12
BOTULINUM TOXIN TYPE A	4	10
CARBIDOPA ANHYDROUS	4	9
RIVAROXABAN	4	9
APIXABAN	4	8
ROSUVASTATIN	4	8
ATORVASTATIN	4	7
FINGOLIMOD	4	6
TICAGRELOR	4	6
DABIGATRAN ETEXILATE	4	5
ABCIXIMAB	4	4
EDARAVONE	4	4
EDOXABAN	4	4
HYDROXYUREA	4	4
ONABOTULINUMTOXINA	4	4
ACETAMINOPHEN	4	3
COLCHICINE	4	3
DONEPEZIL	4	3
EPTIFIBATIDE	4	3
LEVODOPA	4	3
MANNITOL	4	3
MARAVIROC	4	3
NIMODIPINE	4	3
SORBITOL	4	3
VORAPAXAR	4	3